Nasal Discharge Scores Research Articles

Multi-omics reveals that alkaline mineral water improves the respiratory health and growth performance of transported calves

BackgroundLong-distance transportation, a frequent practice in the cattle industry, stresses calves and results in morbidity, mortality, and growth suppression, leading to welfare concerns and economic losses. Alkaline mineral water (AMW) is an electrolyte additive containing multiple mineral elements and shows stress-mitigating effects on humans and bovines.ResultsHere, we monitored the respiratory health status and growth performance of 60 Simmental calves subjected to 30 hours of road transportation using a clinical scoring system. Within the three days of commingling before the transportation and 30 days after the transportation, calves in the AMW group (n = 30) were supplied with AMW, while calves in the Control group (n = 29) were not. On three specific days, namely the day before transportation (day -3), the 30th day (day 30), and the 60th day (day 60) after transportation, sets of venous blood, serum, and nasopharyngeal swab samples were collected from 20 calves (10 from each group) for routine blood testing, whole blood transcriptomic sequencing, serology detection, serum untargeted metabolic sequencing, and 16S rRNA gene sequencing. The field data showed that calves in the AMW group displayed lower rectal temperatures (38.967 ℃ vs. 39.022 ℃; p = 0.004), respiratory scores (0.079 vs. 0.144; p < 0.001), appetite scores (0.024 vs. 0.055; p < 0.001), ocular and ear scores (0.185 vs. 0.338; p < 0.001), nasal discharge scores (0.143 vs. 0.241; p < 0.001), and higher body weight gains (30.870 kg vs. 7.552 kg; p < 0.001). The outcomes of laboratory and high throughput sequencing data revealed that the calves in the AMW group demonstrated higher cellular and humoral immunities, antioxidant capacities, lower inflammatory levels, and intestinal absorption and lipogenesis on days -3 and 60. The nasopharynx 16S rRNA gene microbiome analysis revealed the different composition and structure of the nasopharyngeal microflora in the two groups of calves on day 30. Joint analysis of multi-omics revealed that on days -3 and 30, bile secretion was a shared pathway enriched by differentially expressed genes and metabolites, and there were strong correlations between the differentially expressed metabolites and the main genera in the nasopharynx.ConclusionsThese results suggest that AMW supplementation enhances peripheral immunity, nutrition absorption, and metabolic processes, subsequently affecting the nasopharyngeal microbiota and improving the respiratory health and growth performance of transported calves. This investigation provided a practical approach to mitigate transportation stress and explored its underlying mechanisms, which are beneficial for the development of the livestock industry.9KT6u9sWWs8ZH5U7yZx1qCVideo

Diagnosis of Oestrus ovis infestation in sheep by PCR and enzyme-linked immunosorbent assay

The aim of this study was to assess the suitability of PCR and ELISA as diagnostic method in young sheep naturally infested by Oestrus ovis larvae. The experiment was carried out from December 2020 to April 2021 with 39 lambs divided into two groups: infested (n = 26) and control treated group (n = 13). The infested group did not receive treatment against oestrosis, and the control group was treated with closantel (10 mg/kg orally) every 28 days in order to keep the animals as free as possible of O. ovis infestation. The clinical signs varied among animals regardless of the number of recovered larvae of each lamb, however, the thick mucus and mucopurulent nasal discharge scores were less frequent in lambs from treated group. There was no correlation between the nasal discharge score and the number of O. ovis recovered larvae (R² = 0.012, P = 0.165). Three control treated animals only presented first instar larvae (L1) (1 – 4 larvae/animal) which were smaller than L1 found in the lambs of the infested group. Ninety-two percent of the lambs from infested group (24/26) were parasitized by O. ovis with number ranging from 1 to 54 larvae per animal. A gradual increase in plasma IgG (anti-antigen of O. ovis larvae) levels of animals from infested group after the third week of the trial was observed, whereas the control lambs had low levels of IgG until the end of the experiment. The PCR had low sensitivity (26 %) and high specificity (100 %), and it presented poor agreement (k = 0.177) with the larvae detection after the lamb slaughter. The oestrosis clinical signs were not related to larvae infestation intensity and ELISA showed a greater advantage over the PCR technique in identifying animals that are carrying O. ovis.

Clinical and antiviral effect of a single oral dose of famciclovir administered to cats at intake to a shelter

Although famciclovir is efficacious in feline herpesvirus type 1 (FHV-1)-infected cats, effects of a single dose early in disease course have not been reported. In this two part, randomized, masked, placebo controlled study, cats received a single dose of 125 mg famciclovir (n = 43) or placebo (n = 43; pilot study), or 500 mg famciclovir (n = 41) or placebo (n = 40; clinical trial) on entering a shelter. FHV-1 PCR testing was performed, bodyweight and food intake were recorded, and signs of respiratory disease were scored prior to and 7 days following treatment. FHV-1 DNA was detected in 40% of cats in both parts at study entry. In the pilot study, ocular and nasal discharge scores increased from days 1 to 7 in famciclovir and placebo treated cats. Sneezing scores increased and bodyweight decreased in famciclovir-treated cats. The proportion of cats in which FHV-1 DNA was detected increased over time in all cats in the pilot study. In the clinical trial, food intake and median clinical disease scores for nasal discharge and sneezing increased from days 1 to 7 in both groups and demeanor scores worsened in famciclovir-treated cats. The proportion of cats shedding FHV-1 DNA was greater on day 7 than on day 1 in cats receiving 500 mg famciclovir. A single dose of famciclovir (125 or 500 mg) administered at shelter intake was not efficacious in a feline population in which 40% were already shedding FHV-1.

Randomized masked controlled clinical trial to compare 7-day and 14-day course length of doxycycline in the treatment of Mycoplasma felis infection in shelter cats

The aim of this study was to compare the clinical and microbial efficacy of a 7-day or a 14-day course of doxycycline for the treatment of Mycoplasma felis-infected cats with clinical signs of upper respiratory tract disease (URTD) assessed using clinical scoring criteria. Cats were randomly allocated to either the Doxy-7 group (N=20; 7-day course of oral doxycyline liquid followed by 7-days placebo); or the Doxy-14 group (N=20; 14-day course of oral doxycycline). There were no significant differences in Mycoplasma load between groups at Day 1 or Day 7 (P>0.05), but at Day 14 mean Mycoplasma load was lower in the Doxy-14 group (P=0.01). Mycoplasma load reduced over Days 1-7 in each group (P<0.01), but only the Doxy-14 group had a significantly reduced Mycoplasma load at Day 14 compared to Day 1 (P<0.01). On Day 14, 11 (55%) cats in the Doxy-7 group and 5 (25%) cats in the Doxy-14 group had positive PCR results for M. felis. There was a statistically significant reduction within each group across the Day 1-7 period for ocular discharge, nasal discharge, demeanor, and food intake scores (P<0.01 for each score category). Nasal discharge scores and sneezing scores were statistically lower in the Doxy-14 group than in the Doxy-7 group on individual days during the Day 8-14 period (P<0.05). We conclude that in M. felis-infected cats with clinical signs of URTD, a 14-day course of oral doxycycline produced superior microbial but not clinical results compared to a 7-day course of treatment.

Comparison of Efficacy of Mometasone Furoate versus Clarithromycin in the Treatment of Chronic Rhinosinusitis without Nasal Polyps in Chinese Adults

Although both nasal steroids and macrolide antibiotics have been recommended for the treatment of chronic rhinosinusitis without nasal polyps (CRSsNPs), whether there is any difference in their clinical efficacy remains unexplored. In addition, few studies have investigated their clinical efficacy in a Chinese population living in China, who present distinct inflammatory patterns compared with white patients in western countries. This study compares the efficacy of mometasone furoate and clarithromycin treatment in CRSsNP in Chinese adults in a preliminary prospective, open-label, randomized trial. Forty-three CRSsNP patients were randomized to receive mometasone furoate nasal spray at 200 μg (n = 21) or clarithromycin tablet at 250 mg (n = 22) once daily for 12 weeks. Patients were assessed before the treatment and after 4, 8, and 12 weeks after treatment. Subjective symptoms were scored on a visual analog scale. Endoscopy physical findings were scored according to Lanza-Kennedy scoring system. Moreover, smoking and atopic status and coexistence of allergic rhinitis (AR) and asthma were recorded. Before the treatment, no significant difference in symptoms and nasal endoscopic physical findings were found between mometasone furoate and clarithromycin group. As early as 4 weeks after dosing, a significant reduction of total symptom scores, nasal obstruction, headache, rhinorrhea and overall burden scores, and mucosal swelling and nasal discharge scores were observed in both groups. No significant difference in symptom or endoscopic scores was observed between these two groups at any posttreatment observation time point. The coexistence of AR was correlated with lower scores of mucosal edema and nasal secretion in the mometasone furoate group after 12-week treatment. Mometasone furoate and clarithromycin show a comparable clinical effect for CRSsNPs in Chinese adults. Mometasone furoate is more effective in improving edema and secretion for CRSsNP patients with concomitant AR.

Effects of Saline Sprays on Symptoms after Endoscopic Sinus Surgery

Topical saline is commonly recommended after endoscopic sinus surgery. The efficacy in this situation has never been shown. We performed a controlled clinical trial to determine the effect of saline sprays on symptoms after endoscopic sinus surgery. Patients were randomized to receive normal saline (NS; n = 20), buffered hypertonic saline (HS; n = 20), or no spray (n = 20). A questionnaire measured symptoms of nasal obstruction, discharge, pain, headache, and trouble sleeping. Daily pain medication usage was recorded. Symptom scores over the first 5 postoperative days showed higher nasal discharge scores in the HS group. Day-by-day comparisons showed that the HS group reported significantly higher pain scores during some postoperative days. The NS group showed similar scores to control. NS and HS sprays do not have a beneficial effect on symptoms compared with no treatment. HS sprays enhanced nasal drainage and pain. Our results do not support prescribing saline sprays early after sinus surgery but do not exclude the use of topical saline in other forms or for other uses, although they may be used for other intentions.